Bryan, Garnier & Co leads the placement of the shares of Mauna Kea Technologies held by Creadev

Bryan, Garnier & Co leads the placement of the shares of Mauna Kea Technologies held by Creadev

News published on May Friday 23, 2014
Share on
Paris, May 16, 2014 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the success of the secondary placement of Mauna Kea Technologies shares held by Creadev. This transaction enlarges Mauna Kea Technologies investors’ base to new French, European and American investors and allows a significant increase of the free float.

This secondary placement led by Bryan, Garnier & Co in the form of an accelerated bookbuilding between May 14 and 15 of more than €20m. This transaction was completed on May 15 in the morning. Following the transaction, Creadev’s stake, previously ca.17%, is below 3% of the outstanding shares.

Bertrand de Talhouët, CEO of CREADEV declares: "We are delighted to have supported Mauna Kea Technologies during the last ten years and to hand over to a group of American and European investors, including Healthcare specialists, having investment strategies more in line with Mauna Kea’s profile."

Virginie Lazès, Managing Partner, adds: "Bryan Garnier is pleased to assist Creadev in this transaction and to contribute to the enlargement of the company’s investor base especially beyond France. This transaction confirms our capacity to provide optimal liquidity solutions for private investors in European small caps."

Hervé Ronin, Managing Director, Healthcare, "With five transactions since the beginning of the year, this transaction confirms the leadership of Bryan, Garnier & Co on public small and mid-cap transactions, especially in the Healthcare sector, to actively manage their shareholding structure, their liquidity and their fundraisings."

Cédric Moreau, Director, Healthcare, "This large secondary placement highlights that investors are confident in the potential of the Mauna Kea’s lead product, Cellvizio, in the very promising optical biopsy sector."

About CREADEV
www.creadev.fr

Creadev is a French private equity firm controlled by the Mulliez Family. It was founded in 2002 and works hands in hands with entrepreneurs in high-potential companies with a long-term perspective in four main sectors: Healthcare, Environment/Energy, Digital Services... ibute to the enlargement of the company’s investor base especially beyond France. This transaction confirms our capacity to provide optimal liquidity solutions for private investors in European small caps."

About MAUNA KEA TECHNOLOGIES
www.maunakeatech.fr

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops, and markets innovative tolls to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, bleary and pancreatic duct, lungs, and during fine needle aspiration procedures. Cellvizio has also been cleared by SFDA in China and MHLW in Japan for use in the GI, respiratory and urinary tract. biopsy sector." 

About Bryan, Garnier & Co
www.bryangarnier.com

Bryan, Garnier & Co is an independent investment bank specialized in European growth companies, providing them with Equity Research & Brokerage, Asset Management and Corporate Finance services. With more than 120 professionals based in London, Paris, New York, Geneva and New Delhi, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique. Bryan, Garnier & Co is a leading advisor to European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital market, LBOs and private placement. Bryan, Garnier & Co is authorized and regulated by the Financial Conduct Authority (FCA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities